ESLA
EstrellaยทNASDAQ
--
--(--)
--
--(--)
ESLA Profile
Estrella Immunopharma, Inc.
A preclinical-stage biopharmaceutical company developing T-cell therapies
Biological Technology
03/30/2022
09/14/2021
NASDAQ Stock Exchange
3
12-31
Common stock
5858 Horton Street, Suite 370, Emeryville, California 94608
--
Estrella Immunopharma, Inc., was incorporated in Delaware on March 30, 2022. The Company is a clinical-stage biopharmaceutical company utilizing its proprietary ARTEMIS technology to develop T-cell therapies for hematological cancers and solid tumors. Its main drug candidate EB103 targets CD19 for the treatment of B-cell malignancies, while a dual-targeted drug candidate EB104 is also being developed.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
